Adherencia al tratamiento en artritis reumatoide: condición indispensable para el control de la enfermedad

Adherencia al tratamiento en artritis reumatoide: condición indispensable para el control de la enfermedad

Bibliographic Details
Main Authors:	Camilo Ruiz Mejía, Ana María Parada Pérez, Andrea Urrego Vásquez, Daniel Gallego González
Format:	Article
Language:	Spanish
Published:	Editorial Ciencias Médicas
Series:	Revista Cubana de Medicina General Integral
Subjects:	arthritis rheumatoid medication adherence antirheumatic agents
Online Access:	http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252016000300015&lng=en&tlng=en

Similar Items

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide
by: Licia Maria Henrique da Mota, et al.

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
by: Kichul Shin, et al.
Published: (2020-01-01)

Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study
by: Morrison A, et al.
Published: (2021-09-01)

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study
by: Yusuke Kashiwado, et al.
Published: (2022-06-01)

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis
by: Kichul Shin, et al.
Published: (2022-09-01)

The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis
by: Der-Yuan Chen, et al.
Published: (2022-12-01)

Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis
by: Licia Maria Henrique da Mota, et al.
Published: (2012-04-01)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
by: John Tesser, et al.
Published: (2023-11-01)

Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model
by: Santos-Moreno P, et al.
Published: (2022-11-01)

Factores sociodemográficos y severidad radiológica de la artritis reumatoide
by: Regino Rodríguez Acosta, et al.
Published: (2001-10-01)

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
by: Ronaldo José Faria, et al.
Published: (2022-04-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
by: Marshall A, et al.
Published: (2019-05-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study
by: Boulos Haraoui, et al.
Published: (2018-10-01)

Potenciais interações medicamentosas em pacientes com artrite reumatoide Potential drug interactions in patients with rheumatoid arthritis
by: Fabíola Bagatini, et al.
Published: (2011-02-01)

Perfil de utilización de los anti-factor de necrosis tumoral en pacientes de Colombia
by: Jorge Machado, et al.
Published: (2011-03-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
by: Małgorzata Wisłowska
Published: (2022-05-01)

Risk of New-Onset Diabetes Mellitus Associated with Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Nationwide Population Study
by: So Hye Nam, et al.
Published: (2022-04-01)

Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
by: Taylor PC, et al.
Published: (2018-10-01)

Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
by: Ivan Padjen, et al.
Published: (2020-12-01)

First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study
by: Paula Muilu, et al.
Published: (2020-07-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY® compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
by: Tsutomu Takeuchi, et al.
Published: (2023-04-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database
by: Hata T, et al.
Published: (2022-08-01)

Inmunopatogenia de la artritis reumatoidea: Conceptos actuales
by: Virginia Torres Lima, et al.
Published: (1998-10-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

Mangosteen ethanol extract alleviated the severity of collagen-induced arthritis in rats and produced synergistic effects with methotrexate
by: Jian Zuo, et al.
Published: (2018-01-01)

iTRAQ and PRM-Based Proteomic Analysis Provides New Insights into Mechanisms of Response to Triple Therapy in Patients with Rheumatoid Arthritis
by: Chen J, et al.
Published: (2021-12-01)

Active tuberculosis infection in moroccan patients with rheumatic diseases under biologic therapy: A multicenter national study
by: Ilham Aachari, et al.
Published: (2022-01-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS
by: V. N. Amirdzhanova, et al.
Published: (2014-09-01)